LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases

Journal of Neuro-Oncology

Volumn 122, Issue 1, 2015, Pages 121-126

  Ahmed, Kamran A ^a   Freilich, Jessica M ^a   Sloot, Sarah ^a   Figura, Nicholas ^b   Gibney, Geoffrey T ^a   Weber, Jeffrey S ^a   Sarangkasiri, Siriporn ^a   Chinnaiyan, Prakash ^a   Forsyth, Peter A ^a   Etame, Arnold B ^a   Rao, Nikhil G ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Brain metastases; Stereotactic radiosurgery; Stereotactic radiotherapy; Vemurafenib

Indexed keywords

INTERLEUKIN 2; IPILIMUMAB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PD1 INHIBITOR; PROTEIN INHIBITOR; STEROID; UNCLASSIFIED DRUG; VEMURAFENIB; INDOLE DERIVATIVE; SULFONAMIDE;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN METASTASIS; CANCER RADIOTHERAPY; COHORT ANALYSIS; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LINEAR ACCELERATOR; MAJOR CLINICAL STUDY; MALE; MELANOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; ONSET AGE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RADIATION DOSE; RADIATION NECROSIS; SCALP REACTION; SEIZURE; SKIN TOXICITY; STEREOTACTIC RADIOSURGERY; TREATMENT DURATION; TREATMENT FAILURE; TUMOR RECURRENCE; TUMOR VOLUME; VERTIGO; VERY ELDERLY; BRAIN; BRAIN NEOPLASMS; CANCER STAGING; CASE CONTROL STUDY; MAGNETIC AND ELECTROMAGNETIC EQUIPMENT; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; RADIOSURGERY; SECONDARY; SURVIVAL RATE; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BRAIN; BRAIN NEOPLASMS; CASE-CONTROL STUDIES; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDOLES; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PARTICLE ACCELERATORS; PROGNOSIS; RADIOSURGERY; SULFONAMIDES; SURVIVAL RATE; YOUNG ADULT;

EID: 84925484636     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-014-1685-x     Document Type: Article

References (25)

1. Staudt M, Lasithiotakis K, Leiter U, Meier F, Eigentler T, Bamberg M, Tatagiba M, Brossart P, Garbe C (2010) Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer 102:1213–1218. doi:10.1038/sj.bjc.6605622
2. Hwu WJ, Lis E, Menell JH, Panageas KS, Lamb LA, Merrell J, Williams LJ, Krown SE, Chapman PB, Livingston PO, Wolchok JD, Houghton AN (2005) Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer 103:2590–2597. doi:10.1002/cncr.21081
3. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Brocker EB, LeBoit PE, Pinkel D, Bastian BC (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135–2147. doi:10.1056/NEJMoa050092
4. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954. doi:10.1038/nature00766
5. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, Burton EA, Wong B, Tsang G, West BL, Powell B, Shellooe R, Marimuthu A, Nguyen H, Zhang KY, Artis DR, Schlessinger J, Su F, Higgins B, Iyer R, D’Andrea K, Koehler A, Stumm M, Lin PS, Lee RJ, Grippo J, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, Chapman PB, Flaherty KT, Xu X, Nathanson KL, Nolop K (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467:596–599. doi:10.1038/nature09454
6. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O’Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, Group BS (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507–2516. doi:10.1056/NEJMoa1103782
7. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, Puzanov I, Hauschild A, Robert C, Algazi A, Mortier L, Tawbi H, Wilhelm T, Zimmer L, Switzky J, Swann S, Martin AM, Guckert M, Goodman V, Streit M, Kirkwood JM, Schadendorf D (2012) Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13:1087–1095. doi:10.1016/S1470-2045(12)70431-X
8. Kefford RMM, Arance A, Nathan P, Blank C, Francoise MA, Gonzalez R, Schachter J, Margolin K, Lasserre SF, Veronese L, McArthur G Vemurafenib (2013) Metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicenter study. In: 10th international meeting of the Society for Melanoma Research, Philadelphia
9. Dummer R, Goldinger SM, Turtschi CP, Eggmann NB, Michielin O, Mitchell L, Veronese L, Hilfiker PR, Felderer L, Rinderknecht JD (2014) Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer 50:611–621. doi:10.1016/j.ejca.2013.11.002
10. Anker CJ, Ribas A, Grossmann AH, Chen X, Narra KK, Akerley W, Andtbacka RH, Noyes RD, Shrieve DC, Grossmann KF (2013) Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma. J Clin Oncol 31:e283–e287. doi:10.1200/JCO.2012.44.7755
11. Boussemart L, Boivin C, Claveau J, Tao YG, Tomasic G, Routier E, Mateus C, Deutsch E, Robert C (2013) Vemurafenib and radiosensitization. JAMA Dermatol 149:855–857. doi:10.1001/jamadermatol.2013.4200
12. Schulze B, Meissner M, Wolter M, Rodel C, Weiss C (2014) Unusual acute and delayed skin reactions during and after whole-brain radiotherapy in combination with the BRAF inhibitor vemurafenib. Two case reports. Strahlenther Onkol 190:229–232. doi:10.1007/s00066-013-0474-3
13. Narayana A, Mathew M, Tam M, Kannan R, Madden KM, Golfinos JG, Parker EC, Ott PA, Pavlick AC (2013) Vemurafenib and radiation therapy in melanoma brain metastases. J Neurooncol 113:411–416. doi:10.1007/s11060-013-1127-1
14. Gaudy-Marqueste C, Carron R, Delsanti C, Loundou A, Monestier S, Archier E, Richard MA, Regis J, Grob JJ (2014) On demand Gamma-knife strategy can be safely combined with BRAF-inhibitors for the treatment of melanoma brain metastases. Ann Oncol. doi:10.1093/annonc/mdu266
15. Shaw E, Scott C, Souhami L, Dinapoli R, Kline R, Loeffler J, Farnan N (2000) Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys 47:291–298
16. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. doi:10.1016/j.ejca.2008.10.026
17. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366:707–714. doi:10.1056/NEJMoa1112302
18. Rochet NM, Dronca RS, Kottschade LA, Chavan RN, Gorman B, Gilbertson JR, Markovic SN (2012) Melanoma brain metastases and vemurafenib: need for further investigation. Mayo Clin Proc 87:976–981. doi:10.1016/j.mayocp.2012.07.006
19. Rochet NM, Kottschade LA, Markovic SN (2011) Vemurafenib for melanoma metastases to the brain. N Engl J Med 365:2439–2441. doi:10.1056/NEJMc1111672
20. Sambade MJ, Peters EC, Thomas NE, Kaufmann WK, Kimple RJ, Shields JM (2011) Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032. Radiother Oncol 98:394–399. doi:10.1016/j.radonc.2010.12.017
21. Harding JJ, Barker CA, Carvajal RD, Wolchok JD, Chapman PB, Lacouture ME (2014) Cutis verticis gyrata in association with vemurafenib and whole-brain radiotherapy. J Clin Oncol 32:e54–e56. doi:10.1200/JCO.2013.49.3528
22. Huang V, Hepper D, Anadkat M, Cornelius L (2012) Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway. Arch Dermatol 148:628–633. doi:10.1001/archdermatol.2012.125
23. Mori Y, Kondziolka D, Flickinger JC, Kirkwood JM, Agarwala S, Lunsford LD (1998) Stereotactic radiosurgery for cerebral metastatic melanoma: factors affecting local disease control and survival. Int J Radiat Oncol Biol Phys 42:581–589
24. Seung SK, Sneed PK, McDermott MW, Shu HK, Leong SP, Chang S, Petti PL, Smith V, Verhey LJ, Wara WM, Phillips TL, Larson DA (1998) Gamma knife radiosurgery for malignant melanoma brain metastases. Cancer J Sci Am 4:103–109
25. Selek U, Chang EL, Hassenbusch SJ 3rd, Shiu AS, Lang FF, Allen P, Weinberg J, Sawaya R, Maor MH (2004) Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases. Int J Radiat Oncol Biol Phys 59:1097–1106. doi:10.1016/j.ijrobp.2003.12.037